Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 20/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 8/20 | 0.71 |
| ▸ | NR4A1 | P22736 | 2/20 | 0.71 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.71 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.71 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517803 | 0.92 | DHODH (1.00) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL4397445 | 0.89 | DHODH (0.80) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL14418192 | 0.85 | DHODH (0.73) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| Vidofludimus SCHEMBL247888 | 0.83 | DHODH (1.00) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| Vidofludimus SCHEMBL29352865 | 0.83 | DHODH (1.00) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL14418129 | 0.83 | DHODH (0.72) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL4386482 | 0.83 | DHODH (0.80) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| Vidofludimus SCHEMBL28974266 | 0.82 | DHODH (0.98) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL14418170 | 0.81 | DHODH (0.68) | DHODHNR4A2NR4A1JMJD7NR4A3 | |
| SCHEMBL14418181 | 0.81 | DHODH (0.76) | DHODHNR4A2NR4A1JMJD7NR4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION | 2016-10-06 | — | — | US | disclosed |
| EP-3071199-A2 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | Genzyme Corporation (US) | 2016-09-28 | — | — | EP | disclosed |
| WO-2015077535-A2 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | GENZYME CORPORATION (US) | 2015-05-28 | — | — | WO | disclosed |
| EP-1581477-B1 | CYCLOALKENE DICARBOXYLIC ACID COMPOUNDS AS ANTI-INFLAMMATORY, IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS | 4SC AG (DE) | 2009-12-02 | — | — | EP | disclosed |
| US-20070224672-A1 | Method of Identifying Inhibitors of DHODH | LEBAN JOHANN | 2007-09-27 | — | — | US | disclosed |
| US-20070224672-A1 | Method of Identifying Inhibitors of DHODH | LEBAN JOHANN | 2007-09-27 | — | — | US | disclosed |
| US-7247736-B2 | Method of identifying inhibitors of DHODH | 4SC AG (DE) | 2007-07-24 | — | — | US | disclosed |
| US-7247736-B2 | Method of identifying inhibitors of DHODH | 4SC AG (DE) | 2007-07-24 | — | — | US | disclosed |
| US-7247736-B2 | Method of identifying inhibitors of DHODH | 4SC AG (DE) | 2007-07-24 | — | — | US | disclosed |
| US-20070027193-A1 | Method of identifying inhibitors of DHODH | 4SC AG (DE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027193-A1 | Method of identifying inhibitors of DHODH | 4SC AG (DE) | 2007-02-01 | — | — | US | disclosed |
| US-20070027193-A1 | Method of identifying inhibitors of DHODH | 4SC AG (DE) | 2007-02-01 | — | — | US | disclosed |
| US-7071355-B2 | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4 SC AG (DE) | 2006-07-04 | — | — | US | disclosed |
| EP-1581478-A1 | DHODH-INHIBITORS AND METHOD FOR THEIR IDENTIFICATION | 4SC AG (DE) | 2005-10-05 | — | — | EP | disclosed |
| US-20040176458-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | 4 SC AG (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-2004056747-A1 | DHODH-INHIBITORS AND METHOD FOR THEIR IDENTIFICATION | 4SC AG (DE) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027193-A1 | Method of identifying inhibitors of DHODH | DHODH, SQOR, NDUFA5 | DHODH 1/4885NR4A2 2196/4885NR4A1 2976/4885 |
| US-20040176458-A1 | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents | MSR1, PPARG, PPARA | DHODH 2089/4885NR4A2 8/4885NR4A1 11/4885 |
| US-20160287549-A1 | NOVEL METHODS FOR TREATING NEURODEGENERATIVE DISEASES | DHODH, DLD, HAGH | DHODH 1/4885NR4A2 2728/4885NR4A1 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.